Current Treatment Options for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Investigators summarize current literature surrounding the treatment of NLPHL and discuss treatment considerations for 2 clinical cases.
Investigators summarize current literature surrounding the treatment of NLPHL and discuss treatment considerations for 2 clinical cases.
Adults treated for Hodgkin lymphoma have an increased risk of death from heart disease, interstitial lung disease, infections, and adverse effects of therapy.
Depending on the type and stage of lymphoma, physicians may choose to avoid having their patients undergo radiation therapy for fear of potential toxic effects in organs.
Among patients with early-stage, favorable Hodgkin lymphoma, treatment regimens with conventional chemotherapy may be effective in a subset of patients.
Responses were also observed in patients previously treated with HDAC or mTOR inhibitors.
Combined modality therapy for early-stage favorable HL yielded excellent outcomes and limited excess radiation doses to organs at risk.
The expanded approval was based on data from the randomized, open-label, phase 3 KEYNOTE-204 trial.
Findings suggest that brentuximab vedotin plus nivolumab was well tolerated and active in older patients with previously untreated HL with comorbidities.
Although 1 in 1000 lymphoma diagnoses occurs in pregnancy, literature on best practices for treatment in this patient group is limited.
Investigators characterized the risks of stage- and cause-specific mortality among patients with classical Hodgkin lymphoma treated with chemotherapy.